Psilocybin for Smoking Cessation: The Johns Hopkins Evidence

Nicotine addiction is among the most persistent and lethal substance use disorders globally, causing approximately 8 million deaths annually. Despite a range of approved pharmacological treatments — nicotine replacement therapy (NRT), varenicline (Chantix), bupropion — long-term abstinence rates remain low. A 12-month quit rate of 25% for NRT and roughly 33% for varenicline (the most effective approved medication) represents the current ceiling.

Against this backdrop, a small pilot study conducted at Johns Hopkins University produced results so far outside normal parameters that the addiction research community took notice: 67% of participants remained abstinent at 12 months. This figure, from the Johnson et al. smoking cessation study, has not been replicated by any approved treatment and stands as one of the strongest signals in the early psychedelic research literature.

The Johnson Studies

Matthew Johnson and Roland Griffiths at Johns Hopkins initiated a pilot study of psilocybin-assisted therapy for smoking cessation in 2014. The study enrolled 15 adult smokers who had made multiple prior quit attempts and who were highly motivated to stop.

Participants received cognitive-behavioral therapy (CBT) for smoking cessation in preparation for and following psilocybin sessions. Most participants received two to three psilocybin sessions at moderate to high doses over a structured timeline aligned with a target quit date. At 6-month follow-up, 80% of participants showed biochemically verified abstinence. At 12 months, the figure was 67%.

A follow-up assessment published in 2017 reported outcomes at 16 months and beyond, finding that roughly 60% of participants remained abstinent — a rate that had never been achieved in addiction treatment research with any agent. Several participants reported not having smoked again since their psilocybin session.

Why These Numbers Matter

To understand the significance, consider the context. Nicotine replacement products achieve 12-month quit rates of approximately 15-25% in rigorous trials. Varenicline, a partial nicotinic receptor agonist considered the most effective pharmacological treatment, achieves roughly 30-35% at 12 months. Behavioral interventions alone perform at 5-15%.

The 67% figure from the Johns Hopkins pilot is more than double the best available pharmaceutical option. The sample size was small (15 participants), the design was open-label, and the study cannot be considered definitive. But the effect size is large enough that even accounting for selection bias and placebo effects, it demands explanation.

A larger randomized controlled trial comparing psilocybin-assisted therapy to extended varenicline treatment was subsequently funded and conducted, with results expected to further clarify the comparison.

The Mechanism: Identity Reconsolidation

The dominant theoretical explanation for psilocybin's effectiveness in smoking cessation is what researchers call motivational reconsolidation or identity shift. Smoking is not merely a habit — it is identity-embedded. Smokers often describe themselves as "someone who smokes," and the cigarette is woven into self-concept, social rituals, and emotional regulation.

Psilocybin appears to create conditions under which that identity can be examined from the outside. Participants frequently describe viewing their relationship to cigarettes from a new vantage point during the psilocybin experience — observing the pattern as something separate from themselves rather than as part of who they are.

Many participants report a qualitative shift: smoking becomes irrelevant. Not the white-knuckle suppression of cravings, but a fundamental change in how cigarettes figure in their self-concept. Some describe disgust — a visceral revision of what cigarettes represent. Others describe the experience of smoking as simply no longer belonging to who they discovered themselves to be during the session.

This is distinct from how other cessation treatments work. NRT reduces withdrawal symptoms. Varenicline blocks nicotine's rewarding effect. Psilocybin appears to operate at the level of meaning — changing what smoking means to the person who smokes.

The Role of Cognitive-Behavioral Therapy Support

The Hopkins protocol was not psilocybin alone. Participants received structured CBT sessions covering the psychology of addiction, craving management, behavioral strategies for the early quit period, and preparation for the psilocybin experience itself. Integration sessions following psilocybin sessions helped participants connect the experiences to their quit attempt.

This structure is important. Psilocybin may create a window of neuroplasticity and identity flexibility, but without structured support to direct that opening toward behavioral change, outcomes may be less consistent. The CBT component gave participants tools to use during that window.

Implications for Addiction Treatment

The tobacco findings are significant beyond smoking itself. Nicotine addiction is considered highly intractable — arguably the most pharmacologically reinforcing legal substance. If psilocybin can achieve such outcomes with nicotine, the implications for other substance use disorders are substantial.

The Hopkins group has conducted or initiated studies for alcohol use disorder, cocaine use disorder, and opioid use disorder using similar frameworks. The model — structured preparation, high-dose psilocybin experience, structured integration with relevant behavioral therapy — appears transferable across substances, though efficacy will need to be established independently for each.

For tobacco specifically, the evidence base remains limited to pilot-scale work. Those seeking help with smoking cessation should consult their physician about evidence-based options and watch for clinical trial opportunities as the research advances.